Drugs / Hemay028
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04100642 | Apr → Oct 2019 | — | Tianjin Hemay Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04352595 | Apr 2020 → Feb 2021 | atopic eczema | Tianjin Hemay Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hemay028 | “This is a first-in-human study in health volunteers. The purpose is the local tolerability and systemic safety of Hemay808, which is an ointment made of a novel small molecule Hemay028.” NCT04100642 ↗1“Hemay808 is a onitment of Hemay028, a small molecule PDE4 inhibitor.” NCT04352595 ↗ |
| Action | Inhibit | “a small molecule PDE4 inhibitor” NCT04352595 ↗ |
| Modality | Small molecule | “a novel small molecule Hemay028” NCT04100642 ↗ |
| Route | Topical | “Hemay808 is a onitment of Hemay028” NCT04352595 ↗ |